Search research articles
Contact Us
Filters
Showing results (341-350 of 590) with videos related to
Page
of 59
Sort By:
Journal of Acquired Immune Deficiency Syndromes
|
October 1, 1994
Relationship of beta 2 microglobulin and CD4 counts to neuropsychological performance in HIV-1-infected intravenous drug users
A A Boccellari, D B Chambers, J W Dilley, et al.
Clinical Genitourinary Cancer
|
December 3, 2017
eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer
Neal D Shore, Ronald F Tutrone, Neil F Mariados, et al.
Targeted Oncology
|
December 6, 2022
Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases
Gordon Brown, Laurence Belkoff, Jason M Hafron, et al.
Therapeutic Advances in Medical Oncology
|
May 25, 2026
Real-world comparative effectiveness of apalutamide versus enzalutamide for prostate-specific antigen response in metastatic castration-sensitive prostate cancer
Mehmet A Bilen, Benjamin H Lowentritt, Sabree Burbage, et al.
The Journal of Biological Chemistry
|
September 18, 2001
The distal hinge of the reactive site loop and its proximity: a target to modulate plasminogen activator inhibitor-1 activity
A P Bijnens, A Gils, J M Stassen, et al.
The Journal of Surgical Research
|
October 4, 2011
An evaluation of surgical site infections by wound classification system using the ACS-NSQIP
Gezzer Ortega, Daniel S Rhee, Dominic J Papandria, et al.
The Journal of Clinical Investigation
|
May 1, 1995
Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro
D T Eitzman, W P Fay, D A Lawrence, et al.
BJU International
|
March 19, 2016
Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer
Neal D Shore, Franklin Chu, Judd Moul, et al.
Future Oncology (London, England)
|
April 29, 2026
Real-world clinical outcomes in patients with biochemical recurrence after local therapy for non-metastatic prostate cancer
Neal D Shore, Nasreen Khan, Rana R McKay, et al.
Molecular Psychiatry
|
May 24, 2000
Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium
N L Johnston-Wilson, C D Sims, J P Hofmann, et al.
Page
of 59
Search research articles
Search
Showing results (341-350 of 590) with videos related to
Sort By:
Page
of 59
Journal of Acquired Immune Deficiency Syndromes
|
October 1, 1994
Relationship of beta 2 microglobulin and CD4 counts to neuropsychological performance in HIV-1-infected intravenous drug users
A A Boccellari, D B Chambers, J W Dilley, et al.
Clinical Genitourinary Cancer
|
December 3, 2017
eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer
Neal D Shore, Ronald F Tutrone, Neil F Mariados, et al.
Targeted Oncology
|
December 6, 2022
Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases
Gordon Brown, Laurence Belkoff, Jason M Hafron, et al.
Therapeutic Advances in Medical Oncology
|
May 25, 2026
Real-world comparative effectiveness of apalutamide versus enzalutamide for prostate-specific antigen response in metastatic castration-sensitive prostate cancer
Mehmet A Bilen, Benjamin H Lowentritt, Sabree Burbage, et al.
The Journal of Biological Chemistry
|
September 18, 2001
The distal hinge of the reactive site loop and its proximity: a target to modulate plasminogen activator inhibitor-1 activity
A P Bijnens, A Gils, J M Stassen, et al.
The Journal of Surgical Research
|
October 4, 2011
An evaluation of surgical site infections by wound classification system using the ACS-NSQIP
Gezzer Ortega, Daniel S Rhee, Dominic J Papandria, et al.
The Journal of Clinical Investigation
|
May 1, 1995
Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro
D T Eitzman, W P Fay, D A Lawrence, et al.
BJU International
|
March 19, 2016
Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer
Neal D Shore, Franklin Chu, Judd Moul, et al.
Future Oncology (London, England)
|
April 29, 2026
Real-world clinical outcomes in patients with biochemical recurrence after local therapy for non-metastatic prostate cancer
Neal D Shore, Nasreen Khan, Rana R McKay, et al.
Molecular Psychiatry
|
May 24, 2000
Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium
N L Johnston-Wilson, C D Sims, J P Hofmann, et al.
Page
of 59